Karel Decaestecker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7548344/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intracorporeal Versus Extracorporeal Robot-assisted Kidney Autotransplantation: Experience of the ERUS RAKT Working Group. European Urology, 2022, 81, 168-175.	1.9	17
2	Supportive care needs and utilization of bladder cancer patients undergoing radical cystectomy: A longitudinal study. Psycho-Oncology, 2022, 31, 219-226.	2.3	8
3	Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU International, 2022, 129, 699-707.	2.5	19
4	Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial. European Urology Focus, 2022, 8, 1238-1245.	3.1	6
5	An evidence map and synthesis review with meta-analysis on the risk of incisional hernia in colorectal surgery with standard closure. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2022, 26, 411-436.	2.0	14
6	Clinical outcomes of low-pressure pneumoperitoneum in minimally invasive urological surgery. Journal of Robotic Surgery, 2022, , 1.	1.8	5
7	Methods of Sentinel Lymph Node Detection and Management in Urinary Bladder Cancer—A Narrative Review. Current Oncology, 2022, 29, 1335-1348.	2.2	10
8	European countries have different rates of sperm cryopreservation before vasectomy and at the time of reversal. Andrology, 2022, 10, 1286-1291.	3.5	3
9	Robotic-assisted kidney transplantation in obese recipients compared to non-obese recipients: the European experience. World Journal of Urology, 2021, 39, 1287-1298.	2.2	30
10	Robotâ€assisted kidney transplantation: update from the European Robotic Urology Section (ERUS) series. BJU International, 2021, 127, 222-228.	2.5	39
11	PET–CT for staging patients with muscle invasive bladder cancer: is it more than just a fancy tool?. Clinical and Translational Imaging, 2021, 9, 83-94.	2.1	3
12	Morbidity and mortality after robotâ€assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group. BJU International, 2021, 127, 585-595.	2.5	17
13	Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. European Urology Oncology, 2021, 4, 305-309.	5.4	40
14	Pediatric Challenges in Robot-Assisted Kidney Transplantation. Frontiers in Surgery, 2021, 8, 649418.	1.4	7
15	Analyzing the learning curves of a novice and an experienced urologist for transrectal magnetic resonance imaging-ultrasound fusion prostate biopsy. Translational Andrology and Urology, 2021, 10, 1956-1965.	1.4	4
16	Retrospective analysis of multiparametric MRI to predict complete pathologic response after neo-adjuvant chemotherapy for muscle invasive bladder cancer Journal of Clinical Oncology, 2021, 39, e16535-e16535.	1.6	0
17	Artificial intelligence in urological oncology: An update and future applications. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 379-399.	1.6	13
18	The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. European Urology Open Science, 2021, 29, 68-76.	0.4	23

#	Article	IF	CITATIONS
19	Vulvar pagetoid urothelial intraepithelial neoplasia: a case report. Acta Chirurgica Belgica, 2021, , 1-4.	0.4	1
20	Elective nodal radiotherapy in prostate cancer. Lancet Oncology, The, 2021, 22, e348-e357.	10.7	26
21	Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial. World Journal of Urology, 2021, 39, 357-364.	2.2	2
22	1109 Artificial Intelligence in Urological Oncology. British Journal of Surgery, 2021, 108, .	0.3	0
23	Supportive Roles of the Health Care Team Throughout the Illness Trajectory of Bladder Cancer Patients Undergoing Radical Cystectomy: A Qualitative Study Exploring the Patients' Perspectives. Seminars in Oncology Nursing, 2021, 37, 151226.	1.5	4
24	â€~Full prosthetic jacket': external stenting of the renal vein. Acta Chirurgica Belgica, 2020, 120, 357-360.	0.4	0
25	Robot-assisted nephroureterectomy for upper tract urothelial carcinoma: results from three high-volume robotic surgery institutions. Journal of Robotic Surgery, 2020, 14, 211-219.	1.8	24
26	Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy: Systematic review of the recent literature. International Journal of Urology, 2020, 27, 98-107.	1.0	21
27	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
28	Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review. Quality of Life Research, 2020, 29, 2887-2910.	3.1	14
29	Robot-Assisted Kidney Transplantation. , 2020, , .		2
30	Learning Curve in Robot-assisted Kidney Transplantation: Results from the European Robotic Urological Society Working Group. European Urology, 2020, 78, 239-247.	1.9	54
31	A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer. Cancers, 2020, 12, 132.	3.7	7
32	Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial Journal of Clinical Oncology, 2020, 38, 10-10.	1.6	82
33	Review of the evidence for robotic-assisted robotic cystectomy and intra-corporeal urinary diversion in bladder cancer. Translational Andrology and Urology, 2020, 9, 2946-2955.	1.4	1
34	Total Intracorporeal Robot Kidney Autotransplantation: Case Report and Description of Surgical Technique. Frontiers in Surgery, 2020, 7, 65.	1.4	5
35	V11-04 INNOVATIONS AND TECHNICAL VARIATIONS IN ROBOT-ASSISTED KIDNEY TRANSPLANTATION: RESULT FROM THE ERUS WORKING GROUP. Journal of Urology, 2020, 203, .	۲S 0.4	0
36	MP52-03 THE EUROPEAN EXPERIENCE IN ROBOT-ASSISTED KIDNEY TRANSPLANTATION: LEARNING CURVE. Journal of Urology, 2020, 203, .	0.4	0

#	Article	IF	CITATIONS
37	V11-02â€∱TOTALLY INTRACORPOREAL ROBOT-ASSISTED KIDNEY AUTO-TRANSPLANTATION. Journal of Urology, 2020, 203, .	0.4	0
38	PD22-07â€∱ROBOTIC ASSISTED KIDNEY TRANSPLANTATION: UPDATE FROM THE ERUS SERIES. Journal of Urology, 2020, 203, .	0.4	0
39	Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. World Journal of Urology, 2019, 37, 2565-2571.	2.2	10
40	Pelvic lymph node dissection in prostate cancer staging: evaluation of morbidity and oncological outcomes. Acta Chirurgica Belgica, 2019, 119, 103-109.	0.4	7
41	Castration-resistant prostate cancer-free survival in the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial. European Urology Supplements, 2019, 18, e2044-e2045.	0.1	0
42	Single-setting robot-assisted kidney transplantation consecutive to single-port laparoscopic nephrectomy in a child and robot-assisted living-related donor nephrectomy: initial Ghent experience. Journal of Pediatric Urology, 2019, 15, 578-579.	1.1	8
43	Readressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. BJU International, 2019, 124, 35-39.	2.5	4
44	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology, 2019, 75, 707-711.	1.9	89
45	Radiation Dosimetry and Biodistribution of ¹⁸ F-PSMA-11 for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1736-1742.	5.0	34
46	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. World Journal of Urology, 2019, 37, 1543-1549.	2.2	19
47	Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center. European Journal of Radiology, 2019, 114, 92-98.	2.6	31
48	Predicting perioperative mortality after radical cystectomy: comorbidity assessment tools are only part of the puzzle. Translational Andrology and Urology, 2019, 8, 781-784.	1.4	1
49	EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 2019, 30, 1697-1727.	1.2	96
50	Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within aÂrandomized controlled trial. Strahlentherapie Und Onkologie, 2019, 195, 393-401.	2.0	39
51	Understanding physical activity behavior in patients with bladder cancer before and after radical cystectomy: a qualitative interview study. Clinical Rehabilitation, 2019, 33, 750-761.	2.2	14
52	Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. European Urology, 2019, 75, 826-833.	1.9	48
53	Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. European Urology Focus, 2019, 5, 1007-1013.	3.1	79
54	MP76-15 ROBOT-ASSISTED KIDNEY AUTOTRANSPLANTATION (RAKAT): UPDATE FROM THE FIRST SERIES IN EUROPE. Journal of Urology, 2019, 201, .	0.4	1

#	Article	IF	CITATIONS
55	Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results Journal of Clinical Oncology, 2019, 37, 422-422.	1.6	0
56	Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study. Acta Clinica Belgica, 2018, 73, 1-4.	1.2	4
57	European experience of robotâ€assisted kidney transplantation: minimum of 1â€year followâ€up. BJU International, 2018, 122, 255-262.	2.5	51
58	Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 158.e13-158.e20.	1.6	27
59	4 Weeks Versus 5ÂWeeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 866-870.	0.8	7
60	Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 437-443.	2.4	9
61	Availability of prostate cancer exercise rehabilitation resources and practice patterns in Belgium: Results of a cross-sectional study. European Journal of Cancer Care, 2018, 27, e12788.	1.5	4
62	Robot-assisted Kidney Transplantation: The European Experience. European Urology, 2018, 73, 273-281.	1.9	101
63	A systematic review of exercise and psychosocial rehabilitation interventions to improve health-related outcomes in patients with bladder cancer undergoing radical cystectomy. Clinical Rehabilitation, 2018, 32, 594-606.	2.2	29
64	Re: Active Surveillance for Low-risk Nonmuscle Invasive Bladder Cancer (NMIBC): a Confirmatory and Resource Consumption Study from Bladder Cancer Italian Active Surveillance (BIAS) Project. European Urology, 2018, 73, 478-479.	1.9	0
65	Clinical pathway improves implementation of evidenceâ€based strategies for the management of androgen deprivation therapyâ€induced side effects in men with prostate cancer. BJU International, 2018, 121, 610-618.	2.5	10
66	A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?. Annals of Hematology, 2018, 97, 545-546.	1.8	0
67	Robotic lingual mucosal onlay graft ureteroplasty for proximal ureteral stricture. European Urology Supplements, 2018, 17, e1935.	0.1	7
68	Reply to JE. Bibault et al, B. Tombal, and C. Cattrini et al. Journal of Clinical Oncology, 2018, 36, 2351-2352.	1.6	4
69	Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2018, 36, 446-453.	1.6	972
70	Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer. Translational Andrology and Urology, 2018, 7, S135-S137.	1.4	2
71	Selecting candidates for early discharge after radical cystectomy for bladder cancer. Translational Andrology and Urology, 2018, 7, S86-S89.	1.4	0
72	Exercise prescription dose for castration resistant prostate cancer patients: A phase I prescription dose escalation trial. European Urology Supplements, 2018, 17, e2884.	0.1	0

#	Article	IF	CITATIONS
73	An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers. Translational Andrology and Urology, 2018, 7, S706-S709.	1.4	1
74	Robot-assisted Kidney Autotransplantation: A Minimally Invasive Way to Salvage Kidneys. European Urology Focus, 2018, 4, 198-205.	3.1	32
75	Robot-Assisted kidney transplantation with regional hypothermia using grafts with multiple vessels: Results from the EAU Robotic Urology Section (ERUS) working group. European Urology Supplements, 2018, 17, 214.	0.1	0
76	Robot-assisted Kidney Transplantation with Regional Hypothermia Using Grafts with Multiple Vessels After Extracorporeal Vascular Reconstruction: Results from the European Association of Urology Robotic Urology Section Working Group. European Urology Focus, 2018, 4, 175-184.	3.1	34
77	OC-0059: Four- or 5-weeks of radiotherapy for prostate cancer: interim results of a randomized phase 3 trial. Radiotherapy and Oncology, 2018, 127, S26.	0.6	0
78	SP-0375: Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence. Radiotherapy and Oncology, 2018, 127, S191-S192.	0.6	0
79	OC-0480: Patient-reported outcomes in the search for the optimal radiotherapy schedule for prostate cancer. Radiotherapy and Oncology, 2018, 127, S246-S247.	0.6	0
80	OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma. Radiotherapy and Oncology, 2018, 127, S357-S358.	0.6	1
81	EP-1687: The current place of radiotherapy as treatment option for muscle-invasive bladder cancer. Radiotherapy and Oncology, 2018, 127, S906-S907.	0.6	0
82	Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium. Clinical Genitourinary Cancer, 2018, 16, e1159-e1169.	1.9	6
83	Prospective Randomized Controlled Trial Exploring the Effect of TachoSil on Lymphocele Formation After Extended Pelvic Lymph Node Dissection in Prostate Cancer. Urology, 2018, 118, 134-140.	1.0	14
84	The European experience on robot-assisted kidney transplantation: Minimum of one year follow up. European Urology Supplements, 2018, 17, e1263.	0.1	0
85	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. JMIR Research Protocols, 2018, 7, e11256.	1.0	12
86	MP52-09 MULTICENTRIC PROSPECTIVE LOCAL TREATMENT OF METASTATIC PROSTATE CANCER (LOMP) TRIAL: INTERIM ANALYSIS OF CLINICAL OUTCOMES AND PROGNOSTIC FACTORS. Journal of Urology, 2018, 199, .	0.4	0
87	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 152.e13-152.e22.	1.6	2
88	Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial. Urology, 2017, 106, 146-152.	1.0	42
89	Whole pelvis radiotherapy for pathological node-positive prostate cancer. Strahlentherapie Und Onkologie, 2017, 193, 444-451.	2.0	13
90	Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol BMI Open 2017.7 e016054	1.9	7

#	Article	IF	CITATIONS
91	Release of urinary extracellular vesicles in prostate cancer is associated with altered urinary N-glycosylation profile. Journal of Clinical Pathology, 2017, 70, 838-846.	2.0	18
92	EP-1369: Cystectomy with adjuvant radiotherapy for invasive bladder tumors: early results of a phase II study. Radiotherapy and Oncology, 2017, 123, S734.	0.6	0
93	MP30-03 ROBOTIC KIDNEY TRANSPLANTATION: EUROPEAN ONE-YEAR DATA. Journal of Urology, 2017, 197, .	0.4	1
94	PV-0550: Combined high dose radiation and tyrosine kinase inhibitors in renal cell carcinoma: a phase I trial. Radiotherapy and Oncology, 2017, 123, S293-S294.	0.6	0
95	MP34-15 A EUROPEAN MULTI-CENTRE REPORT ON CURRENT NEOADJUVANT CHEMOTHERAPY ADMINISTRATION RATES IN ROBOT-ASSISTED RADICAL CYSTECTOMY PATIENTS AND THE IMPACT ON PATHOLOGICAL STAGING. Journal of Urology, 2017, 197, .	0.4	0
96	Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in prostate cancer patients. European Urology Supplements, 2017, 16, e2711.	0.1	0
97	A multi-centre review of neoadjuvant chemotherapy administration rates related to Robotic-assisted Radical Cystectomy and the impact on pathological staging. European Urology Supplements, 2017, 16, e2344-e2345.	0.1	0
98	Prevalence and prognosis of lowâ€volume, oligorecurrent, hormoneâ€sensitive prostate cancer amenable to lesion ablative therapy. BJU International, 2017, 120, 815-821.	2.5	53
99	Corrigendum re: "Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group―[Eur Urol 2017;71:723–6]. European Urology, 2017, 72, e80.	1.9	1
100	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 150.	4.4	26
101	Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. BMC Cancer, 2017, 17, 308.	2.6	7
102	Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA. Clinical Radiology, 2017, 72, 23-32.	1.1	78
103	Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group. European Urology, 2017, 71, 723-726.	1.9	51
104	Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients. Diagnostics, 2017, 7, 56.	2.6	8
105	Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiation Oncology, 2017, 12, 157.	2.7	28
106	Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder. Translational Andrology and Urology, 2017, 6, 1117-1122.	1.4	3
107	Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial Journal of Clinical Oncology, 2017, 35, 153-153.	1.6	4
108	Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. European Urology, 2016, 70, 649-660.	1.9	114

#	Article	IF	CITATIONS
109	The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients. International Journal of Radiation Oncology Biology Physics, 2016, 96, 323-332.	0.8	19
110	Nontransecting Anastomotic Repair in Urethral Reconstruction: Surgical and Functional Outcomes. Journal of Urology, 2016, 196, 1679-1684.	0.4	19
111	Ablative Intravesical Chemotherapy for Small Recurrent Non-Muscle-Invasive Bladder Cancer: A Prospective Study. Urologia Internationalis, 2016, 96, 14-19.	1.3	7
112	A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations Journal of Clinical Oncology, 2016, 34, TPS4575-TPS4575.	1.6	6
113	Spontaneous Bladder Wall Rupture Due to Emphysematous Cystitis. Journal of the Belgian Society of Radiology, 2016, 100, 83.	0.2	5
114	Managing the adverse events of intravesical bacillus Calmette–Guérin therapy. Research and Reports in Urology, 2015, 7, 157.	1.0	42
115	Anastomotic Repair versus Free Graft Urethroplasty for Bulbar Strictures: A Focus on the Impact on Sexual Function. Advances in Urology, 2015, 2015, 1-7.	1.3	20
116	Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome. BioMed Research International, 2015, 2015, 1-6.	1.9	26
117	Perineal Urethrostomy: Surgical and Functional Evaluation of Two Techniques. BioMed Research International, 2015, 2015, 1-6.	1.9	20
118	Transurethral Resection of the Prostate in Recurrent Acute Bacterial Prostatitis. Urologia Internationalis, 2015, 94, 442-444.	1.3	8
119	The Correct Sequence of Intravesical Chemotherapy and Bacillus Calmette-Guérin for Non–Muscle-invasive Bladder Cancer. European Urology, 2015, 67, 517-518.	1.9	2
120	Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature. European Urology, 2015, 67, 852-863.	1.9	303
121	Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis. Biochemia Medica, 2015, 25, 439-449.	2.7	10
122	Rectal toxicity after intensity modulated radiotherapy for prostate cancer: Which rectal dose volume constraints should we use?. Radiotherapy and Oncology, 2014, 113, 398-403.	0.6	28
123	Agreement of Gleason Score on Prostate Biopsy and Radical Prostatectomy Specimen: Is There Improvement With Increased Number of Biopsy Cylinders and the 2005 Revised Gleason Scoring?. Clinical Genitourinary Cancer, 2014, 12, 160-166.	1.9	14
124	Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiation Oncology, 2014, 9, 135.	2.7	220
125	Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: Toxicity and matched case comparison with postoperative prostate bed-only radiotherapy. Radiotherapy and Oncology, 2013, 109, 222-228.	0.6	17
126	A novel mutation c.118delA in exon 1 of the androgen receptor gene resulting in complete androgen insensitivity syndrome within a large family. Fertility and Sterility, 2008, 89, 1260.e3-1260.e7.	1.0	7